Maternal psychological distress on delayed onset of lactation II: A meta-analysis
Abstract
Background: Existing studies suggest a potential association between maternal psychological distress and delayed onset of lactation II (DOLII), but the evidence remains inconclusive.
Methods: A systematic literature search was conducted in PubMed, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, China National Knowledge Infrastructure, WANFANG, and VIP databases, from database inception to August 30, 2024. Two independent reviewers screened articles, extracted data, and assessed study quality. Discrepancies were resolved through discussion. Meta-analysis was performed using Revman 5.3 software after data extraction. This review was registered with the International Prospective Register of Systematic Reviews (CRD42024536705).
Results: Pooled effect sizes demonstrated positive associations between the DOLII and postpartum anxiety (odds ratio [OR] = 2.83, 95% confidence interval [CI]: 1.86-4.33), postpartum depression (OR = 2.30, 95% CI: 1.66-3.18), and postpartum fatigue (OR = 1.93, 95% CI: 1.12-3.33). In contrast, the associations between DOLII and prenatal anxiety (OR = 1.34, 95% CI: 0.94-1.92), prenatal depression (OR = 1.44, 95% CI: 0.84-2.48), and fear of labor (OR = 1.30, 95% CI: 0.77-2.19) were not statistically significant.
Conclusions: This study synthesized data from multiple studies to investigate the association between maternal psychological distress and DOLII. However, beyond postpartum depression, there is a…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.